Top Industry Leaders in the Asia-Pacific Interventional Cardiology Market
Received CE Mark approval for its Amplify™ Flex Stent System, designed for improved deliverability and conformability in challenging coronary anatomies.Expanded its portfolio with the launch of the Aveiro™ Renal Denervation System for treating resistant hypertension, potentially offering a minimally invasive alternative to traditional therapies.Announced positive results from the TWENTE-4 trial demonstrating the safety and efficacy of its Ranger™ QBE PTA Balloon Catheter for treating peripheral artery disease.
Medtronic Introduced the Micra AVT™ transcatheter heart valve system offering a minimally invasive option for patients with severe aortic stenosis who are ineligible for traditional surgery.
Terumo Corporation Launched the WINEON™ Stent System featuring a unique design for optimal vessel wall apposition and improved clinical outcomes.Expanded its presence in the Asia-Pacific market through strategic partnerships and acquisitions.
List of Asia-Pacific Interventional Cardiology Key Companies in the Market
- Abbott Laboratories Inc. (U.S.)
- Braun Melsungen AG (Germany)
- R. Bard Inc. (U.S.)
- Abiomed Inc. (U.S)
- Edwards Lifesciences (U.S.)
- Biosensors International Group Ltd. ( Singapore)
- Boston Scientific Corporation (U.S.)
- Medtronic PLC (Ireland)
- Angiodynamics Inc. ( U.S)
- Terumo Medical Corporation (Japan)
- Johnson & Johnson Services Inc. (U.S.).
- Lombard Medical Technologies Plc. (U.K)
- Clearstream Technologies Group Plc. (Ireland)
